Last reviewed · How we verify

NCT05623683: P4ACE

P4ACE Trial for Persons With Chronic Knee Pain

Completed NA Last updated 28 July 2025
What this trial tests

NA trial testing Intermittent Walking in Knee Osteoarthritis in 23 participants. Completed in 31 July 2024.

Timeline
20 April 2023
Primary endpoint
31 July 2024
31 July 2024

Quick facts

Lead sponsorNorthwestern University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designcrossover
Maskingsingle
Primary purposetreatment
Enrollment23
Start date20 April 2023
Primary completion31 July 2024
Estimated completion31 July 2024
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Northwestern University

Who can join

Adults 45 to 75, any sex, with Knee Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this single-blind, cross-over clinical trial is to compare the immediate effect of intermittent vs. continuous walking on clinical and mechanistic pain profiles in persons with knee osteoarthritis (OA). In this cross-over trial, participants will perform two types of walking on a treadmill. Intermittent walking will involve 3 blocks of 10 minutes with 2 blocks of 5-minute rest (sitting on a chair) in-between. Continuous walking will involve resting for 10 minutes (sitting in a chair) before walking on the treadmill for 1 continuous block of 30 minutes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Knee Osteoarthritis

Currently open trials in the same condition.

Other Northwestern University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05623683.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing